Annovis Bio, Inc.

Annovis Bio, Inc. is a promising player in the biotechnology industry, with a compelling slogan emphasizing the urgency for a new approach in treating Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. Established in 2008 and headquartered in the United States, the company has recently secured a $7.50MPost-IPO Equity investment as of 31 October 2023. Annovis is focused on developing novel drug therapies for chronic and acute neurodegeneration, with their lead compound, ANVS-401, showing promising results in both preclinical and clinical studies. ANVS-401, a small, once a day, orally administered, brain penetrant inhibitor of neurotoxic proteins, has demonstrated potential as the first drug to interfere with the underlying mechanism of neurodegeneration. The compound has undergone extensive evaluation in 19 animal studies at renowned institutions such as the Karolinska Institute, Columbia University, and Harvard University. Human clinical trials have also been conducted, including safety studies in 120 healthy volunteers and a proof-of-concept study in five MCI patients, showing promising clinical signals. The company is currently engaged in a Phase 2a study in AD patients in collaboration with the Alzheimer Disease Cooperative Study (ADCS) group, and plans to initiate a second Phase 2a proof-of-concept study of ANVS-401 in the first quarter of 2020 with 50 PD patients. Annovis is driven by the belief that addressing Alzheimer’s and Parkinson’s represents significant unmet medical needs in the aging U.S. population, presenting potentially lucrative markets. Their aspiration is to demonstrate the efficacy of ANVS-401 in both indications, signaling a promising future for the company.